Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Characteristics of study population Characteristics | Total | Familial MS status | p value | First-degree relative | Second-/third-degree relative | No known family history: Vitamin D levels | 61.6 (27.0) | 65.4 (24.9) | 63.4 (25.5) | 61.1 (27.5) | 0.40
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Case-control study.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS.
Source: Abstract.
This study included individuals with MS from the Swedish population-based case: control study Epidemiologic Investigation of Multiple Sclerosis (EIMS) [].
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Family history of multiple sclerosis and long-term outcomes
Case-control study · Journal of Neurology · 2026
Original publication title
Family history of multiple sclerosis and long-term outcomes
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Family history is a well-established risk factor for multiple sclerosis (MS), but its influence on disease progression remains unclear. We investigated whether familial MS, including degree of relatedness, is associated with baseline characteristics and disease outcomes.
Source: BackgroundAbstract: What methods does the paper describe?
We included individuals with incident MS from the Swedish population-based epidemiologic investigation of multiple sclerosis study with longitudinal follow-up through the Swedish MS registry. Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS. Outcomes included confirmed disability worsening (CDW), progression to Expanded Disability Status Scale milestones 3 and 4, cognitive worsening measured by the symbol digit modalities test, MRI disease activity, and worsening on the Multiple Sclerosis Impact Scale-29. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression.
Source: MethodsAbstract: Results
Among 3,094 participants, 239 (7.7%) reported a first-degree relative with MS and 468 (15.1%) reported a second-/third-degree relative with MS. Baseline characteristics were similar across groups, although HLA: DRB1*15:01 positivity was more common among individuals with first-degree familial MS. No significant associations were observed between familial MS status and disability progression, cognitive decline, MRI disease activity, or patient-reported worsening. Compared with individuals without a known family history of MS, the HR for CDW was 1.06 (95% CI 0.89 to 1.30) among individuals with first-degree familial MS and 1.04 (95% CI 0.90 to 1.20) among those with second-/third-degree familial MS.
Source: ResultsAbstract: Conclusions
Family history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.
Source: ConclusionsAuthors’ abstract
Background
Family history is a well-established risk factor for multiple sclerosis (MS), but its influence on disease progression remains unclear. We investigated whether familial MS, including degree of relatedness, is associated with baseline characteristics and disease outcomes.
Methods
We included individuals with incident MS from the Swedish population-based epidemiologic investigation of multiple sclerosis study with longitudinal follow-up through the Swedish MS registry. Participants were categorized as having no family history of MS, first-degree familial MS, or second-/third-degree familial MS. Outcomes included confirmed disability worsening (CDW), progression to Expanded Disability Status Scale milestones 3 and 4, cognitive worsening measured by the symbol digit modalities test, MRI disease activity, and worsening on the Multiple Sclerosis Impact Scale-29. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox regression.
Results
Among 3,094 participants, 239 (7.7%) reported a first-degree relative with MS and 468 (15.1%) reported a second-/third-degree relative with MS. Baseline characteristics were similar across groups, although HLA: DRB1*15:01 positivity was more common among individuals with first-degree familial MS. No significant associations were observed between familial MS status and disability progression, cognitive decline, MRI disease activity, or patient-reported worsening. Compared with individuals without a known family history of MS, the HR for CDW was 1.06 (95% CI 0.89 to 1.30) among individuals with first-degree familial MS and 1.04 (95% CI 0.90 to 1.20) among those with second-/third-degree familial MS.
Conclusions
Family history of MS did not appear to have a substantial prognostic impact on long-term disease outcomes after MS onset.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00415-026-14162-9.
Publication and source details
Original title: Family history of multiple sclerosis and long-term outcomes
Anna Karin Hedström; Tomas Olsson; Lars Alfredsson
Journal of Neurology · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/501100004359Vetenskapsrådet2016-023492020-019982024-02565Alfredsson Lars http://dx.doi.org/10.13039/501100006636Forskningsrådet om Hälsa, Arbetsliv och Välfärd2015-001952019-00697Hedström Anna Karin Alfredsson Lars swedish brain foundationFO2020-0077FO2024-0344Hedström Anna Karin Alfredsson Lars http://dx.doi.org/10.13039/501100006310Medicinska ForskningsrådetMargaretha af Ugglas FoundationRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-10T21:38:26.196904+00:00
DOI: 10.1007/s00415-026-14162-9 · PMC13615947